What 'legal highs' actually are — unscheduled novel psychoactive substances sold in UK/EU head shops — and why they are not the same as the Schedule I classic psychedelics this site covers.
"Legal highs" is an informal term, mostly used in the UK and EU, for novel psychoactive substances (NPS) — synthetic cannabinoids, synthetic stimulants and cathinones, and other lab-made compounds designed to produce drug-like effects while falling outside existing drug-scheduling lists. Through roughly the 2000s and early 2010s, these products were sold openly in "head shops" and online under brand names (often unrelated to their actual chemistry) as incense, bath salts, or plant food — labeling meant to dodge consumer-protection rules rather than describe the product.
The core feature of a "legal high" is definitional, not chemical: it is legal specifically because a regulator has not yet added that exact molecule to a controlled-substances list. Manufacturers responded to each new ban by tweaking the molecule slightly, producing a fast-moving cycle of new, technically unscheduled compounds that regulators struggled to keep up with.
No, and this is the most common confusion Autocomplete and search traffic reveals. The classic psychedelics covered throughout this site — psilocybin, LSD, DMT, and mescaline — are internationally scheduled substances (Schedule I federally in the US) with decades of chemical characterization and a growing body of clinical research behind them. See our what psychedelics are legal in the US guide for exactly where each one stands.
"Legal highs," by contrast, are substances that have not been scheduled — often because their chemistry changes faster than any single country's regulator can list it. That is a regulatory gap, not a safety endorsement. A compound sold as a "legal high" may have no published human safety data at all, while a scheduled classic psychedelic typically has a well-documented pharmacological profile even though it remains illegal to possess.
Not in the way they were before 2016. The UK's Psychoactive Substances Act 2016 banned the production, sale, and supply of any substance "capable of producing a psychoactive effect" that was not otherwise exempted — alcohol, caffeine, nicotine, and medicines are specifically exempt. That blanket approach, rather than trying to list every individual molecule, closed most of the UK head shops that had sold NPS products under the "legal highs" label. Some novel substances are still sold in other jurisdictions with looser NPS rules or through online sellers operating across borders, and new compounds continue to appear faster than any single country's schedule can track.
This site covers psychedelic-assisted therapy and the researched, scheduled classic psychedelics — not the NPS/"legal highs" market. We are addressing the term here because a meaningful volume of search traffic uses "legal highs" and "legal psychedelics" interchangeably, and conflating the two categories is itself a safety risk: someone looking for information on psilocybin or LSD should not end up buying an unstudied synthetic cannabinoid instead. If you are trying to understand the legal status of an actual classic psychedelic, start with our psychedelic glossary or the US legal status guide.
'Legal highs' is an informal term, mostly used in the UK and EU, for novel psychoactive substances (NPS) — synthetic cannabinoids, synthetic stimulants, and other lab-made compounds designed to produce drug-like effects while falling outside existing drug-scheduling lists. They were historically sold openly in head shops and online under brand names disconnected from their actual chemistry.
No. The classic psychedelics covered on this site — psilocybin, LSD, DMT, mescaline — are internationally scheduled substances (Schedule I in the US) with decades of chemical characterization and a growing body of clinical research behind them. 'Legal highs' are, by definition, substances that have not been scheduled, often because their chemistry changes faster than regulators can list it. Unscheduled does not mean studied or safe.
Not in the way they were before 2016. The UK's Psychoactive Substances Act 2016 banned the sale of any substance capable of producing a psychoactive effect that was not otherwise exempted (alcohol, caffeine, nicotine, and medicines are exempt), which closed most of the UK head shops that had sold NPS products under the 'legal highs' label. Some novel substances are still sold in other jurisdictions with looser NPS rules, and new compounds continue to appear faster than any single country's schedule can track.
Unregulated NPS products carry unknown-purity and unknown-dose risk — the actual compound in a product sold as a 'legal high' can vary by batch, and its pharmacology may never have been studied in humans. Scheduled classic psychedelics carry their own legal risk, but their chemistry and typical dose range are well characterized in the research literature, a meaningfully different risk profile than a synthetic compound with no safety data.
Get psychedelic law research & policy updates
New trials, FDA decisions, and legal changes for psychedelic law — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.